A detailed history of Allspring Global Investments Holdings, LLC transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Allspring Global Investments Holdings, LLC holds 11,281 shares of NTLA stock, worth $161,318. This represents 0.0% of its overall portfolio holdings.

Number of Shares
11,281
Previous 10,887 3.62%
Holding current value
$161,318
Previous $243,000 4.94%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 18, 2024

BUY
$19.72 - $27.36 $7,769 - $10,779
394 Added 3.62%
11,281 $231,000
Q2 2024

Jul 26, 2024

BUY
$20.02 - $27.22 $39,899 - $54,249
1,993 Added 22.41%
10,887 $243,000
Q1 2024

Apr 18, 2024

BUY
$23.82 - $32.8 $17,865 - $24,599
750 Added 9.21%
8,894 $244,000
Q4 2023

Jan 25, 2024

BUY
$23.16 - $32.34 $13,479 - $18,821
582 Added 7.7%
8,144 $248,000
Q3 2023

Oct 27, 2023

BUY
$31.62 - $45.78 $239,110 - $346,188
7,562 New
7,562 $239,000
Q2 2023

Jul 18, 2023

BUY
$34.58 - $46.03 $117,329 - $156,179
3,393 Added 79.35%
7,669 $312,000
Q1 2023

Apr 13, 2023

SELL
$33.3 - $44.82 $27,172 - $36,573
-816 Reduced 16.03%
4,276 $159,000
Q4 2022

Jan 23, 2023

SELL
$33.21 - $62.69 $2,158 - $4,074
-65 Reduced 1.26%
5,092 $0
Q3 2022

Oct 26, 2022

SELL
$53.92 - $71.7 $15,798 - $21,008
-293 Reduced 5.38%
5,157 $288,000
Q2 2022

Jul 25, 2022

SELL
$38.49 - $76.21 $964,020 - $1.91 Million
-25,046 Reduced 82.13%
5,450 $282,000
Q1 2022

May 02, 2022

SELL
$58.27 - $118.99 $88,570 - $180,864
-1,520 Reduced 4.75%
30,496 $2.22 Million
Q4 2021

Jan 28, 2022

BUY
$100.76 - $138.36 $3.23 Million - $4.43 Million
32,016 New
32,016 $3.79 Million

Others Institutions Holding NTLA

About Intellia Therapeutics, Inc.


  • Ticker NTLA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,011,800
  • Market Cap $1.09B
  • Description
  • Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...
More about NTLA
Track This Portfolio

Track Allspring Global Investments Holdings, LLC Portfolio

Follow Allspring Global Investments Holdings, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Allspring Global Investments Holdings, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Allspring Global Investments Holdings, LLC with notifications on news.